Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK4 inhibitor (Insilico Medicine)
- Development stage
- Preclinical
- Lead developer
- InSilico Medicine
- Modality
- Small Molecules
01
Overview
CDK4 inhibitor (Insilico Medicine) is a preclinical small-molecule inhibitor specifically targeting cyclin-dependent kinase 4 (CDK4). Developed by Insilico Medicine using its proprietary generative AI platform, the compound is intended for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The drug is designed to be highly selective for CDK4 over the closely related CDK6, with the goal of maintaining potent anti-tumor activity while minimizing the hematological toxicities, such as neutropenia, that are commonly associated with non-selective CDK4/6 inhibitors. It is currently in the hit-to-lead or preclinical stage of development.
- Other names
- CDK4 inhibitorCDK-4 inhibitorCDK 4 inhibitor
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on CDK4 inhibitor (Insilico Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK4 inhibitor (Insilico Medicine).